The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.

Abstract

Drug delivery nanocarriers, especially targeted drug delivery by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal therapeutics enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake. Here, we highlight the features of immunoliposomes that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While a large number of studies has been published, the emphasis here is placed on the carbonic anhydrase IX (CA-IX) and the conjugated liposomes that are likely to open a new chapter on drug delivery system by using immunoliposomes to deliver anticancer ingredients to cancer cells in vivo.

• Authors: Huei Leng Helena Ng, Aiping Lu, Ge Lin, Ling Qin, Zhijun Yang
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 16 Issue 1 Pg. 230-55 (Dec 24 2014) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 25547490 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Liposomes
• Carbonic Anhydrases

Topics

• Animals
• Antineoplastic Agents (administration & dosage, pharmacokinetics)
• Carbonic Anhydrases (chemistry)
• Humans
• Liposomes (chemistry, pharmacokinetics)